AbbVie and Xilio Partner to Develop Next-Gen Immunotherapies
AbbVie and Xilio join forces to advance tumor-activated immunotherapies, including masked T-cell engagers.
AbbVie and Xilio Therapeutics have announced a strategic collaboration to advance tumor-activated immunotherapies, including innovative masked T-cell engagers. Xilio’s proprietary platform technology enables selective activation of biologics within the tumor microenvironment, aiming to enhance efficacy while minimizing systemic side effects. This partnership aligns with AbbVie's commitment to developing next-generation oncology treatments that improve patient outcomes.
As part of the agreement, Xilio will receive $52 million in upfront payments, including a $10 million equity investment, with the potential for up to $2.1 billion in milestone payments and tiered royalties. Industry leaders from both companies expressed enthusiasm about leveraging their combined expertise in protein engineering and oncology research to push the boundaries of cancer immunotherapy.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Plus dans Pharma News
Tous les articles →
Medicus Pharma soumet à la FDA le protocole de Phase 2b/3 pour Teverelix
Fresenius Kabi reçoit une lettre d’avertissement de la FDA après des défaillances d’enquête sur le traitement aseptique dans l’établissement de Melrose Park
Discussion